<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36969170</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses.</ArticleTitle><Pagination><StartPage>1043680</StartPage><MedlinePgn>1043680</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1043680</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2023.1043680</ELocationID><Abstract><AbstractText>Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders. Here, we characterized KZR-616 <i>in vitro</i> and <i>in vivo</i> using multiplexed cytokine analysis, lymphocyte activation and differentiation, and differential gene expression analysis. KZR-616 blocked production of &gt;30 pro-inflammatory cytokines in human peripheral blood mononuclear cells (PBMCs), polarization of T helper (Th) cells, and formation of plasmablasts. In the NZB/W F1 mouse model of lupus nephritis (LN), KZR-616 treatment resulted in complete resolution of proteinuria that was maintained at least 8 weeks after the cessation of dosing and was mediated in part by alterations in T and B cell activation, including reduced numbers of short and long-lived plasma cells. Gene expression analysis of human PBMCs and tissues from diseased mice revealed a consistent and broad response focused on inhibition of T, B, and plasma cell function and the Type I interferon pathway and promotion of hematopoietic cell lineages and tissue remodeling. In healthy volunteers, KZR-616 administration resulted in selective inhibition of the immunoproteasome and blockade of cytokine production following <i>ex vivo</i> stimulation. These data support the ongoing development of KZR-616 in autoimmune disorders such as systemic lupus erythematosus (SLE)/LN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Muchamuel, Fan, Anderl, Bomba, Johnson, Lowe, Tuch, McMinn, Millare and Kirk.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muchamuel</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>R Andrea</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderl</LastName><ForeName>Janet L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bomba</LastName><ForeName>Darrin J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Henry W B</ForeName><Initials>HWB</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuch</LastName><ForeName>Brian B</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMinn</LastName><ForeName>Dustin L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millare</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirk</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Research, Kezar Life Sciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O4BT6C02M2</RegistryNumber><NameOfSubstance UI="C000712054">KZR-616</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="Y">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SLE - systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immunoproteasome</Keyword><Keyword MajorTopicYN="N">lupus nephritis (LN)</Keyword><Keyword MajorTopicYN="N">plasma cells</Keyword></KeywordList><CoiStatement>All authors are or were employed by Kezar Life Sciences at the time the work was completed and are shareholders of Kezar Life Science. In addition, the research in this manuscript was fully funded by Kezar Life Sciences. The funder had the following involvement in the study: study design, data collection and analysis, decision to publish and preparation of the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>27</Day><Hour>3</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36969170</ArticleId><ArticleId IdType="pmc">PMC10036830</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2023.1043680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fanouriakis A, Bertsias G. Changing paradigms in the treatment of systemic lupus erythematosus. Lupus Sci Med (2019) 6(1):e000310. doi: 10.1136/lupus-2018-000310</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000310</ArticleId><ArticleId IdType="pmc">PMC6519431</ArticleId><ArticleId IdType="pubmed">31168398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. . Systemic lupus erythematosus. Nat Rev Dis Primers (2016) 2:16039. doi: 10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. . Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell (2016) 165(3):551&#x2013;65. doi: 10.1016/j.cell.2016.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.03.008</ArticleId><ArticleId IdType="pmc">PMC5426482</ArticleId><ArticleId IdType="pubmed">27040498</ArticleId></ArticleIdList></Reference><Reference><Citation>Marion TN, Postlethwaite AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol (2014) 36(5):495&#x2013;517. doi: 10.1007/s00281-014-0440-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-014-0440-x</ArticleId><ArticleId IdType="pubmed">25102991</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalina MD, Owen KA, Labonte AC, Grammer AC, Lipsky PE. The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus. J Autoimmun (2020) 110:102359. doi: 10.1016/j.jaut.2019.102359</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102359</ArticleId><ArticleId IdType="pubmed">31806421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 127(2):303&#x2013;12. doi: 10.1016/j.jaci.2010.12.1087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2010.12.1087</ArticleId><ArticleId IdType="pmc">PMC3053574</ArticleId><ArticleId IdType="pubmed">21281862</ArticleId></ArticleIdList></Reference><Reference><Citation>Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M. The immunoproteasome: A novel drug target for autoimmune diseases. Clin Exp Rheumatol (2015) 33(4 suppl 92):S74&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">26458097</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk CJ, Muchamuel T, Wang J, Fan RA. Discovery and early clinical development of selective immunoproteasome inhibitors. Cells (2021) 11(1). doi: 10.3390/cells11010009</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11010009</ArticleId><ArticleId IdType="pmc">PMC8750005</ArticleId><ArticleId IdType="pubmed">35011570</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi J, Zhuang R, Kong L, He R, Zhu H, Zhang J. Immunoproteasome-selective inhibitors: an overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem (2019) 182:111646. doi: 10.1016/j.ejmech.2019.111646</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.111646</ArticleId><ArticleId IdType="pubmed">31521028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Zhu H, Shao J, He R, Xi J, Zhuang R, et al. . Immunoproteasome-selective inhibitors: The future of autoimmune diseases? Future Med Chem (2020) 12(4):269&#x2013;72. doi: 10.4155/fmc-2019-0299</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2019-0299</ArticleId><ArticleId IdType="pubmed">31983229</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano G, Cafiero C, Divella C, Sallustio F, Gigante M, Pontrelli P, et al. . Local synthesis of interferon-alpha in lupus nephritis is associated with type I interferons signature and LMP7 induction in renal tubular epithelial cells. Arthritis Res Ther (2015) 17:72. doi: 10.1186/s13075-015-0588-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0588-3</ArticleId><ArticleId IdType="pmc">PMC4389585</ArticleId><ArticleId IdType="pubmed">25889472</ArticleId></ArticleIdList></Reference><Reference><Citation>Basler M, Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, et al. . Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med (2014) 6(2):226&#x2013;38. doi: 10.1002/emmm.201303543</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201303543</ArticleId><ArticleId IdType="pmc">PMC3927957</ArticleId><ArticleId IdType="pubmed">24399752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, et al. . Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheumatol (2012) 64(2):493&#x2013;503. doi: 10.1002/art.33333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33333</ArticleId><ArticleId IdType="pmc">PMC4584406</ArticleId><ArticleId IdType="pubmed">21905015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalim KW, Basler M, Kirk CJ, Groettrup M. Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol (2012) 189(8):4182&#x2013;93. doi: 10.4049/jimmunol.1201183</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1201183</ArticleId><ArticleId IdType="pubmed">22984077</ArticleId></ArticleIdList></Reference><Reference><Citation>Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, et al. . A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 15(7):781&#x2013;7. doi: 10.1038/nm.1978</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1978</ArticleId><ArticleId IdType="pubmed">19525961</ArticleId></ArticleIdList></Reference><Reference><Citation>Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, et al. . Co-Inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity. EMBO Rep (2018) 19(12):e46512. doi: 10.15252/embr.201846512</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201846512</ArticleId><ArticleId IdType="pmc">PMC6280796</ArticleId><ArticleId IdType="pubmed">30279279</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson HWB, Lowe E, Anderl JL, Fan A, Muchamuel T, Bowers S, et al. . Required immunoproteasome subunit inhibition profile for anti-inflammatory efficacy and clinical candidate KZR-616 ((2 S,3 r)- n-(( s)-3-(cyclopent-1-en-1-yl)-1-(( r)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( s)-2-(2-morpholinoacetamido)propanamido)propenamide). J Med Chem (2018) 61(24):11127&#x2013;43. doi: 10.1021/acs.jmedchem.8b01201</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b01201</ArticleId><ArticleId IdType="pubmed">30380863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer BF, Moser K, Hauser AE, Peddinghaus A, Voigt C, Eilat D, et al. . Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 199(11):1577&#x2013;84. doi: 10.1084/jem.20040168</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20040168</ArticleId><ArticleId IdType="pmc">PMC2211779</ArticleId><ArticleId IdType="pubmed">15173206</ArticleId></ArticleIdList></Reference><Reference><Citation>Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature (1997) 388(6638):133&#x2013;4. doi: 10.1038/40540</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/40540</ArticleId><ArticleId IdType="pubmed">9217150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. . STAR: ultrafast universal RNA-seq aligner. Bioinformatics (2013) 29(1):15&#x2013;21. doi: 10.1093/bioinformatics/bts635</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinf (2011) 12:323. doi: 10.1186/1471-2105-12-323</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-323</ArticleId><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol (2014) 15(12):550. doi: 10.1186/s13059-014-0550-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene set enrichment analysis. bioRxiv (2019). doi:&#xa0;10.1101/060012v3</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/060012v3</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A, et al. . The reactome pathway knowledgebase. Nucleic Acids Res (2020) 48(D1):D498&#x2013;503. doi: 10.1093/nar/gkz1031</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1031</ArticleId><ArticleId IdType="pmc">PMC7145712</ArticleId><ArticleId IdType="pubmed">31691815</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 27(12):1739&#x2013;40. doi: 10.1093/bioinformatics/btr260</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btr260</ArticleId><ArticleId IdType="pmc">PMC3106198</ArticleId><ArticleId IdType="pubmed">21546393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC. Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol Res (2018) 6(11):1388&#x2013;400. doi: 10.1158/2326-6066.CIR-18-0342</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0342</ArticleId><ArticleId IdType="pubmed">30266715</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. . A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity (2008) 29(1):150&#x2013;64. doi: 10.1016/j.immuni.2008.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.05.012</ArticleId><ArticleId IdType="pmc">PMC2727981</ArticleId><ArticleId IdType="pubmed">18631455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zyla J, Marczyk M, Domaszewska T, Kaufmann SHE, Polanska J, Weiner J. Gene set enrichment for reproducible science: comparison of CERNO and eight other algorithms. Bioinformatics (2019) 35(24):5146&#x2013;54. doi: 10.1093/bioinformatics/btz447</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz447</ArticleId><ArticleId IdType="pmc">PMC6954644</ArticleId><ArticleId IdType="pubmed">31165139</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F, et al. . Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun (2005) 6(4):319&#x2013;31. doi: 10.1038/sj.gene.6364173</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364173</ArticleId><ArticleId IdType="pubmed">15789058</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi W, Liao Y, Willis SN, Taubenheim N, Inouye M, Tarlinton DM, et al. . Transcriptional profiling of mouse b cell terminal differentiation defines a signature for antibody-secreting plasma cells. Nat Immunol (2015) 16(6):663&#x2013;73. doi: 10.1038/ni.3154</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3154</ArticleId><ArticleId IdType="pubmed">25894659</ArticleId></ArticleIdList></Reference><Reference><Citation>Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W, et al. . Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol (2012) 189(2):988&#x2013;1001. doi: 10.4049/jimmunol.1103031</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103031</ArticleId><ArticleId IdType="pmc">PMC3392438</ArticleId><ArticleId IdType="pubmed">22723521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer A, Green J, Pollard J, Jr., Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics (2014) 30(4):523&#x2013;30. doi: 10.1093/bioinformatics/btt703</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt703</ArticleId><ArticleId IdType="pmc">PMC3928520</ArticleId><ArticleId IdType="pubmed">24336805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lickliter J, Anderl J, Kirk CJ, Wang J, Bomba D. KZR-616, a selective inhibitor of the immunoproteasome, shows a promising safety and sarget inhibition profile in a phase I, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers [abstract]. Arthritis Rheumatol (2017) 69(suppl 10). doi: 10.1136/annrheumdis-2018-eular.3344</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-eular.3344</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SJ, Levitsky K, Parlati F, Bennett MK, Arastu-Kapur S, Kellerman L, et al. . Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: Application of a novel pharmacodynamic assay. Br J Haematol (2016) 173(6):884&#x2013;95. doi: 10.1111/bjh.14014</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.14014</ArticleId><ArticleId IdType="pmc">PMC5074317</ArticleId><ArticleId IdType="pubmed">27071340</ArticleId></ArticleIdList></Reference><Reference><Citation>Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. . Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 282(5396):2085&#x2013;8. doi: 10.1126/science.282.5396.2085</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.282.5396.2085</ArticleId><ArticleId IdType="pubmed">9851930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Basler M, Alvarez G, Brunner T, Kirk CJ, Groettrup M. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation. Kidney Int (2018) 93(3):670&#x2013;80. doi: 10.1016/j.kint.2017.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.09.023</ArticleId><ArticleId IdType="pubmed">29229189</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T, Sarfert R, Klotsche J, Kuhl AA, Rubbert-Roth A, Lorenz HM, et al. . The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis (2015) 74(7):1474&#x2013;8. doi: 10.1136/annrheumdis-2014-206016</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206016</ArticleId><ArticleId IdType="pmc">PMC4484251</ArticleId><ArticleId IdType="pubmed">25710470</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. . The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med (2008) 14(7):748&#x2013;55. doi: 10.1038/nm1763</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1763</ArticleId><ArticleId IdType="pubmed">18542049</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol (2012) 24(6):651&#x2013;7. doi: 10.1016/j.coi.2012.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2012.10.004</ArticleId><ArticleId IdType="pmc">PMC3508331</ArticleId><ArticleId IdType="pubmed">23131610</ArticleId></ArticleIdList></Reference><Reference><Citation>Long H, Yin H, Wang L, Gershwin ME, Lu Q. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J Autoimmun (2016) 74:118&#x2013;38. doi: 10.1016/j.jaut.2016.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2016.06.020</ArticleId><ArticleId IdType="pubmed">27396525</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol (2016) 12(12):716&#x2013;30. doi: 10.1038/nrrheum.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.186</ArticleId><ArticleId IdType="pubmed">27872476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis (2009) 11(4):290&#x2013;7. doi: 10.1111/j.1399-3062.2009.00407.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-3062.2009.00407.x</ArticleId><ArticleId IdType="pmc">PMC2852585</ArticleId><ArticleId IdType="pubmed">19497072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballas SK, Tabbara KF, Murphy DL, Mohandas N, Clark MR, Shohet SB. Erythrocyte deformability changes in autoimmune hemolytic anemia during development of NZB mice and their (NZB/NZW)F1 hybrid. J Clin Lab Immunol (1985) 16(4):217&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">4020852</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalesi N, Korani S, Korani M, Johnston TP, Sahebkar A. Bortezomib: A proteasome inhibitor for the treatment of autoimmune diseases. Inflammopharmacology (2021) 29(5):1291&#x2013;306. doi: 10.1007/s10787-021-00863-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00863-2</ArticleId><ArticleId IdType="pubmed">34424482</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, et al. . Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood (2009) 114(16):3439&#x2013;47. doi: 10.1182/blood-2009-05-223677</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-05-223677</ArticleId><ArticleId IdType="pubmed">19671918</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Koerner J, Basler M, Brunner T, Kirk CJ, Groettrup M. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors. Kidney Int (2019) 95(3):611&#x2013;23. doi: 10.1016/j.kint.2018.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.10.022</ArticleId><ArticleId IdType="pubmed">30685098</ArticleId></ArticleIdList></Reference><Reference><Citation>Minnich M, Tagoh H, Bonelt P, Axelsson E, Fischer M, Cebolla B, et al. . Multifunctional role of the transcription factor blimp-1 in coordinating plasma cell differentiation. Nat Immunol (2016) 17(3):331&#x2013;43. doi: 10.1038/ni.3349</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3349</ArticleId><ArticleId IdType="pmc">PMC5790184</ArticleId><ArticleId IdType="pubmed">26779602</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, Gravallese EM, et al. . Plasma cell differentiation requires the transcription factor XBP-1. Nature (2001) 412(6844):300&#x2013;7. doi: 10.1038/35085509</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35085509</ArticleId><ArticleId IdType="pubmed">11460154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity (2006) 25(2):225&#x2013;36. doi: 10.1016/j.immuni.2006.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.07.009</ArticleId><ArticleId IdType="pubmed">16919487</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap DYH, Chan TM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis&#x2013;role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci (2019) 20(24):6231. doi: 10.3390/ijms20246231</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20246231</ArticleId><ArticleId IdType="pmc">PMC6940927</ArticleId><ArticleId IdType="pubmed">31835612</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu RT, Zhang P, Yang CL, Pang Y, Zhang M, Zhang N, et al. . ONX-0914, a selective inhibitor of immunoproteasome, ameliorates experimental autoimmune myasthenia gravis by modulating humoral response. J Neuroimmunol (2017) 311:71&#x2013;8. doi: 10.1016/j.jneuroim.2017.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2017.08.005</ArticleId><ArticleId IdType="pubmed">28844501</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet (2019) 393(10188):2344&#x2013;58. doi: 10.1016/S0140-6736(19)30546-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Narain S, Furie R. Update on clinical trials in systemic lupus erythematosus. Curr Opin Rheumatol (2016) 28(5):477&#x2013;87. doi: 10.1097/BOR.0000000000000311</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000311</ArticleId><ArticleId IdType="pubmed">27314466</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan B, Tsuji WH, Chindalore VL, Geppert TD, Rudinskaya A, Pardo P, et al. . Administration of AMG 557, a human anti-B7RP-1 (ICOSL) antibody, leads to the selective inhibition of anti-KLH IgG responses in subjects with SLE: Results of a phase 1 randomized, double-blind, placebo-controlled, sequential, rising, multiple-dose study [abstract]. Arthritis Rheumatol (2013) 65:1743.</Citation></Reference><Reference><Citation>Wikenheiser DJ, Stumhofer JS. ICOS co-stimulation: Friend or foe? Front Immunol (2016) 7:304. doi: 10.3389/fimmu.2016.00304</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00304</ArticleId><ArticleId IdType="pmc">PMC4979228</ArticleId><ArticleId IdType="pubmed">27559335</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: From pathophysiology to clinical assessment. Ann Rheum Dis (2006) 65(2):144&#x2013;8. doi: 10.1136/ard.2005.041673</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.041673</ArticleId><ArticleId IdType="pmc">PMC1798007</ArticleId><ArticleId IdType="pubmed">16079164</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A, Bethunaickan R, Berthier C, Sahu R, Zhang W, Kretzler M. Molecular studies of lupus nephritis kidneys. Immunol Res (2015) 63(1-3):187&#x2013;96. doi: 10.1007/s12026-015-8693-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-015-8693-6</ArticleId><ArticleId IdType="pubmed">26376897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>